Synthetic Biologics' Novel IBS-C Program Featured in American College of Gastroenterology Poster

Synthetic Biologics, Inc. (NYSE MKT: SYN) announced that experimental results supporting the proposed therapeutic mode-of-action of SYN-010 in irritable bowel syndrome with constipation (IBS-C) were presented today in a poster at the American College of Gastroenterology (ACG) Annual Meeting in Honolulu, HI. The research was sponsored by Synthetic Biologics and performed at Cedars-Sinai under the direction of Mark Pimentel, M.D., FRCP(C), Director of Cedars-Sinai Medical Center's (CSMC) GI Motility Program and Laboratory, and Chairman of Synthetic Biologics' IBS-C Clinical Advisory Board. "The presentation at the ACG Annual Meeting highlighted the therapeutic potential of SYN-010 for IBS-C," stated Jeffrey Riley, Chief Executive Officer for Synthetic Biologics. "As we continue to move our IBS-C program through two ongoing Phase 2 clinical trials, this research, along with SYN-010's novel modified-release formulation of the widely prescribed lovastatin lactone, provides a strong body of support for SYN-010's efficacy in reducing methane levels in the gut. We continue to expect topline results from the first Phase See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!